<DOC>
	<DOCNO>NCT02081352</DOCNO>
	<brief_summary>This study design help determine safe effective DermaPure™ may treat hard-to-heal diabetic foot ulcer compare current standard care .</brief_summary>
	<brief_title>A Comparative Efficacy Study DermaPure™ Treat Diabetic Foot Ulcers</brief_title>
	<detailed_description>DermaPure™ decellularized dermal skin substitute use Tissue Regenix dCELL® patent Technology remove cell component human animal tissue maintain native structural biomechanical property . The primary objective study establish wound heal performance safety DermaPure™ 12 week period , administer `` hard heal '' chronic , neuropathic diabetic foot ulcer . This study design compare performance DermaPure™ ( combination standard care ) versus standard care alone .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Type 1 Type 2 diabetes HbA1c ≤12 % Adequate perfusion A full thickness chronic , neuropathic diabetic foot plantar ulcer define Texas Wagner classification . Target ulcer decrease size ( surface area ) less 30 % 2 week screening period . BMI great 45kg/m2 . Presence infection Presence necrosis , purulence sinus tracts remove aggressive debridement . A clinical diagnosis active/acute Charcot neuroarthropathy . Inactive/chronic Charcot exclude patient . Therapy investigational agent drug within 4 week precede screen visit . More 2 week treatment immunosuppressive agent within 3 month enrollment . Evidence malnutrition confirm serum prealbumin level screening . Evidence drug alcohol abuse ,</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Dermis</keyword>
	<keyword>Diabetic foot ulcer</keyword>
	<keyword>Skin substitute</keyword>
	<keyword>Decellularized</keyword>
</DOC>